Public Health Impact Assessment - Guanidinoacetate methyltransferase (GAMT) Deficiency
The webinar features presentations on newborn screening for GAMT, a brief update from the two newborn screening programs currently screening for GAMT in the United States, and an overview of the upcoming public health system impact (PHI) assessment survey for GAMT.
- Dr. Alex Kemper, MD, MPH, MS, Division Chief of Primary Care Pediatrics, Nationwide Children's Hospital.
- Mark Morrissey, PhD, Research Scientist, Newborn Screening, Wadsworth Center, New York State Department of Health
- Kim Hart, MS, LCGC, Program Manager, Newborn Screening Program, Utah Department of Health
- Jelili Ojodu, MPH, Director, Newborn Screening and Genetics, Association of Public Health Laboratories